Sarcoidosis: can tofacitinib slay the dragon?

Nature Reviews Rheumatology, Published online: 23 August 2022; doi:10.1038/s41584-022-00832-1Lack of understanding of the immunology of sarcoidosis has limited therapeutic progress. However, evidence from a small open-label trial suggests that treatment with the Janus kinase inhibitor tofacitinib can improve sarcoidosis symptoms, predominantly by inhibiting type 1 immunity.
Source: Nature Reviews Rheumatology - Category: Rheumatology Authors: Source Type: research